CD19 and acute lymphoblastic leukemia: CD19 CAR-T cell therapy for B-ALL achieved remarkable efficacy with a complete remission of 70–90% (7–9); multiple clinical trials using CD19 CAR-T therapy in RR-ALL have been summarized in Table 1.